CGP 3466B maleate

Research use only, not for human use.

Omigapil maleate is an orally bioavailable GAPDH nitrosylation inhibitor. Omigapil maleate abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice.

Omigapil maleate is an orally bioavailable GAPDH nitrosylation inhibitor. Omigapil maleate abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD).(In Vivo):Treatment with Omigapil (0.1 mg/kg) in 12-week-old dyW/ mag mice results in improved muscle regeneration and increased force .

——

Animal Model:12-week-old dyW/ mag miceDosage:0.1 mg/kg Administration:For the first week of drug treatment, administered once daily by intraperitoneal injection. After weaning (3 weeks of age), applied once daily by oral gavage.Result:Reduced the muscle fibre loss. Many of the functional parameters were significantly improved by omigapil.

Omigapil (Maleate) | Omigapil maleate

Apoptosis

Apoptosis

Bacterial

——

——

200189-97-5

391.42

C23H21NO5

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (127.74 mM)

C(=C\C(O)=O)\C(O)=O.C(N(CC#C)C)C=1C=2C(OC=3C(C1)=CC=CC3)=CC=CC2

——

(-20℃)

With Ice Pack

≥ 2 years